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ABSTRACT 23 
The controls of thirst and sodium appetite are mediated in part by the hormones 24 
aldosterone and angiotensin II (AngII). The present study examined the behavioral and 25 
neural mechanisms of altered effort-value in animals treated with systemic 26 
mineralocorticoids, intracerebroventricular AngII, or both.  First, rats treated with 27 
mineralocorticoid and AngII were tested in the progressive ratio operant task.  The 28 
willingness to work for sodium versus water depended on hormonal treatment.  In 29 
particular, rats treated with both mineralocorticoid and AngII preferentially worked for 30 
access to sodium versus water compared with rats given only one of these hormones.  31 
Second, components of the mesolimbic dopamine pathway were examined for 32 
modulation by mineralocorticoids and AngII.  Based on cFos immunohistochemistry, 33 
AngII treatment activated neurons in the ventral tegmental area and nucleus accumbens, 34 
with no enhancement by mineralocorticoid pretreatment.  In contrast, western blot 35 
analysis revealed that combined hormone treatment increased levels of phospho-tyrosine 36 
hydroxylase in the ventral tegmental area.  Thus, mineralocorticoid and AngII treatments 37 
differentially engaged the mesolimbic pathway based on tyrosine hydroxylase levels 38 
versus cFos activation. 39 
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Introduction 45 
 46 
Fluid depletion can be life threatening, and animals must carefully titrate their 47 
intake of water and sodium to restore and maintain osmotic and volemic balance.   48 
Sodium replacement requires the goal-directed behavior known as sodium appetite 49 
(Andersson, 1977), a behavior that can be prompted by mineralocorticoids, such as 50 
aldosterone, and angiotensin II (AngII) (Johnson and Thunhorst, 1997).  AngII acts in the 51 
brain to elicit water intake and sodium intake (Epstein et al., 1969).  During fluid depletion, 52 
suppression of either central AngII or aldosterone action does not eliminate sodium 53 
appetite, but blocking the central actions of both hormones abolishes the behavior (Buggy 54 
and Jonklaas, 1984; Sakai et al., 1986).  Conversely, when both aldosterone and AngII 55 
are given exogenously, sodium appetite is potentiated (Fluharty and Epstein, 1983).  The 56 
behavioral and neural basis for the combined effect of aldosterone and AngII on sodium 57 
appetite remains undefined.  58 
The behavioral effects aldosterone and AngII to promote sodium ingestion may 59 
involve parallel behavioral mechanisms.  For example, sodium ingestion could be 60 
enhanced by a change in the hedonic strength of the sodium tastant.  Indeed, in rats 61 
placed on a sodium deficient diet, which increases aldosterone and AngII levels, sodium 62 
ingestion is preferred to moderately reinforcing brain stimulation, which suggests sodium 63 
appetite involves the modulation of the pleasurable properties of sodium intake (Conover 64 
et al., 1994).  In parallel to altered taste value, sodium appetite may involve a recalibration 65 
of incentive-based effort.  In this regard, rats treated with both aldosterone and AngII run 66 
faster on a runway to gain access to sodium, compared with rats treated with either 67 
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hormone alone (Zhang et al., 1984), which suggests that the combined hormone 68 
treatment increases the incentive value of sodium.  The progressive ratio task is a 69 
quantitative assay for incentive-based effort, but the effects of combined 70 
mineralocorticoids and AngII on this behavioral test have not been reported.  71 
The mesolimbic dopamine system has been widely implicated in effort-related 72 
behaviors (Barbano and Cador, 2006; Floresco et al., 2008; Kelley et al., 2005; Phillips 73 
et al., 2007; Salamone et al., 2009).  Dopamine neurons in the ventral tegmental area 74 
(VTA) project to the accumbens, which in turn projects to brain regions such as the ventral 75 
pallidum to generate goal directed movement (Carelli, 2002).  Previous work has 76 
implicated this brain system in sodium appetite.  For example, the accumbens receives 77 
multisynaptic input from aldosterone-sensing and sodium-sensing neurons in the 78 
hindbrain (Miller and Loewy, 2014; Shekhtman et al., 2007).  Sodium depletion alters the 79 
level of dopamine transporters and opioid peptides in the accumbens (Grondin et al., 80 
2011; Lucas et al., 2003; Roitman et al., 1999).  In addition, sodium depletion modifies 81 
the dendritic arbor of ventral striatum neurons (Roitman et al., 2002).  Although these 82 
studies have suggested a role for mesolimbic activity in sodium appetite, the separate 83 
effects of aldosterone and AngII on mesolimbic activation have not been studied.   84 
The present studies tested the overall hypothesis that mineralocorticoids and AngII 85 
recalibrate the willingness to work for sodium versus water.  In particular, the willingness 86 
to work was measured with the progressive ratio task.  In addition, the activity of the 87 
mesolimbic dopamine pathway was assessed with immunohistochemistry for cFos and 88 
western blot analysis for tyrosine hydroxylase.  Although it is recognized that sodium 89 
depletion is a complex physiological state that is imperfectly mimicked with 90 
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mineralocorticoid and central AngII treatments, this preparation has yielded useful 91 
insights into the neuroendocrine actions that influence motivated behavior.  92 
 93 
Materials and Methods 94 
Animals 95 
Adult male Sprague-Dawley rats (weight between 225 and 250 g) were obtained 96 
from Charles River Laboratories (Wilmington, MA, USA).  Rats were pair-housed in plastic 97 
tubs with standard bedding and with food and water available ad libitum, except during 98 
experimental procedures.  The temperature in the colony was maintained at 22°C with a 99 
12:12 h reversed light/dark cycle.  Behavioral testing, described below, was conducted 100 
during the lights-out phase.  Animals were allowed at least one week to acclimate to the 101 
colony before any procedures were performed.  The Institutional Animal Care and Use 102 
Committee of the University of Pennsylvania approved all procedures with animals. 103 
 104 
Surgery 105 
Surgeries were performed in aseptic conditions.  Animals were anesthetized with 106 
inducted and maintained with isofluorane anesthesia for stereotaxic surgery. A 26-gauge 107 
guide cannula (Plastics One, Roanoke, VA, USA) was aimed at the lateral ventricle using 108 
these coordinates: 0.48 mm caudal to bregma, 1.6 mm from mid-line and 4.2 mm ventral 109 
to dura mater.  The cannulae were fixed in place with dental cement and bone screws.  110 
Upon completion of surgery procedures, animals were injected with yohimbine (0.11 111 
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mg/kg, ip, Ben Venue Laboratories Bedford, OH), and upon awakening animals were 112 
returned to the housing facility and singly housed. The animals were allowed at least five 113 
days to recover before verification procedures were performed. 114 
Prior to undergoing experimental treatments, animals were tested for correct 115 
lateral ventricle cannula placement and patency.  They were given an icv injection of 20.0 116 
ng of AngII diluted in artificial cerebrospinal fluid (aCSF) via a Hamilton syringe connected 117 
with PE-10 tubing to an injector that terminated 1 mm beyond the guide cannula.  Animals 118 
were excluded from the experiment if they failed to demonstrate a drinking response in 119 
less than 30 seconds, consuming at least 3 ml of water, in two separate AngII challenges.  120 
Experiments began three days after these icv test injections. 121 
 122 
Experimental Design 123 
In all experiments, animals were assigned to one of four treatments in a 2 x 2 124 
design, with a crossover in behavioral experiments.  Animals were first pre-treated twice 125 
daily (10 hours apart) for three days with a subcutaneous injection of sesame oil or an 126 
aldosterone analog, deoxycorticosterone acetate (DOC; 0.25 mg/0.2 ml sesame oil; 127 
Sigma, St Louis, MO).   DOC penetrates the blood brain barrier more easily than 128 
aldosterone due to its low capacity for hydrogen bond formation (Kraulis et al., 1975 ).  129 
Animals then were injected icv with either artificial cerebrospinal fluid (aCSF; R&D 130 
Systems, Minneapolis, MN) or 20.0 ng AngII in a volume of 2.0 ul (Bachem, King of 131 
Prussia, PA).  The treatment groups will be referred to as follows: Veh/Veh, DOC/Veh, 132 
Veh/AngII, DOC/AngII.  Using this experimental design and identical doses, the 133 
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DOC/AngII treatment has been shown to elicit a greater than additive effect on sodium 134 
intake, but not water intake (Grafe et al., 2014).  135 
 136 
Experiment 1. Progressive Ratio Task 137 
Rats were acclimated to wire mesh cages for one hour with two 25-ml bottles 138 
containing tap water and 3% saline, each marked with 0.2 ml graduations.  These bottles 139 
were then removed, and rats were water restricted for 23 hours per day for the next six 140 
days.  During these six days, rats underwent operant lever pressing training in 141 
conditioning boxes for 30 minutes per day (Med Associates; MDPC IV Software, St. 142 
Albans, Vermont).  The conditioning boxes contained levers for both water (right lever) 143 
and 3% saline (left lever), both simultaneously present.  A lever press lowered a syringe 144 
pump, which delivered a 0.1 ml drop of the appropriate liquid into a cup available to the rat. The 145 
saline and water each had their own syringe pump and their own cup. During the first two 146 
training days, to facilitate learning, an aliquot was dispensed every 300 sec that elapsed 147 
without bar pressing.  In addition, animals could earn a 0.1 ml of water or saline for each 148 
bar press, depending on which of the two levers was pressed.  During the subsequent 149 
two training days, the animals earned a 0.1 ml water or saline for each lever press, 150 
followed by two training days during which three lever presses were required for each 151 
aliquot of water or saline. Animals were considered to have learned the lever-fluid 152 
contingencies when they had made at least 10 lever presses for water during the 30-min 153 
session.  Once this occurred, rats were given ad libitum access to water again.  Rats were 154 
then assigned to treatment groups, as described above, and given no further operant 155 
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training while they received their three days of pretreatment injections (vehicle or DOC).  156 
After pretreatment was complete, 24 hours after the last DOC treatment, rats were 157 
administered their assigned icv injection (vehicle or 20 ng AngII), and immediately given 158 
a test with a progressive ratio (PR) schedule. Thus, animals were water replete at the 159 
beginning of the PR test.  The response requirement of the PR schedule increased 160 
progressively for both saline and water, as previously described (Davis et al., 2011).  The 161 
breakpoint for each animal was defined as the final reinforced bar pressing set that 162 
preceded a 10-minute period without earning a reinforcment, with a two-hour limit total.  163 
Food was not available during this task. 164 
 165 
Experiment 2: Hormone-Induced cFos expression 166 
To observe brain activation after DOC and AngII treatments, rats were assigned 167 
to treatment groups, as explained above. Sixty minutes after the last icv injection, each 168 
rat was anesthetized with 50 mg/kg ketamine and 20 mg/kg xylazine, intraperitoneally.  169 
As discussed below, there were group differences in the effort for sodium versus water 170 
during the first few minutes of the progressive ratio task, making 60 minutes post-171 
treatment a reasonable time to expect differences in cFos levels. Rats were perfused 172 
transcardially with 100 mL of heparinized saline followed by 200 ml 4% paraformaldehyde 173 
(Electron Microscopy Sciences, Fort Washington, PA).  The brains were isolated, post-174 
fixed in paraformaldehyde overnight at 4C, and then submerged in 20% sucrose in 0.1 175 
M phosphate buffer for three days.  Coronal sections were cut on a freezing microtome 176 
into three serial sets of 40-um-thick sections.  These sectons encompassed the VTA and 177 
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the shell and core of the accumbens.  One set of sections from each animal underwent 178 
immunohistochemical staining and analysis; the other two sets of sections were 179 
preserved in cryoprotectant as reserve material.   180 
Sections were washed in Tris-buffered saline (TBS; pH 7.4) and then incubated 181 
with a cFos antibody (1:500, sc-52, rabbit; Santa Cruz Biotechnology, Santa Cruz, CA) in 182 
TBS with 0.2% TritonX-100 and 3% normal donkey serum (Jackson Immunoresearch; 183 
West Grove, PA) overnight at 4C.  After several washes, sections were incubated with a 184 
Biotin-SP-conjugated AffiniPure Donkey Anti-rabbit IgG (1:100, Jackson 185 
Immunoresearch) in TBS with 0.2% TritonX-100 and 3% normal donkey serum for 2 hours 186 
at room temperature.  After several washes, sections were incubated with the Vectastain 187 
ABC kit (Vector Laboratories, Burlingame, CA) for one hour.  This was followed by another 188 
set of washes before staining with 3’3’-diaminobenzidine (Sigma-Aldrich) for 10 minutes.  189 
After a final set of washes, sections were mounted on slides, air-dried, and cover slipped 190 
with DPX mounting media (Electron Microscopy Sciences: Fort Washington, PA).   191 
Photomicrographs were acquired with a digital camera (Diagnostic Instruments, 192 
Sterling Heights, MI, model RTKE), maintaining the same microscope and camera 193 
settings to ensure the same level of light and exposure for all images.  Background was 194 
subtracted from images using Photoshop, and images were set to the same threshold 195 
level (200).  Images were further analyzed in NIH Image J using standardized boxes for 196 
each brain region (based on Paxinos & Watson Rat Brain Atlas, shown in Figure 1A), 197 
using the analyze particles function, which counts objects within specific size and shape 198 
parameters.  Pixel size minimum was 15 and circularity was set to 0.35. 199 
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 200 
Experiment 3: Hormone Regulation of Tyrosine Hydroxylase 201 
 Animals were assigned to four treatment groups, as described above.  Five 202 
minutes after the last injections, animals were rapidly decapitated and brains were flash 203 
frozen in hexane over dry ice.  The five-minute time point was selected based on its 204 
correlation with a significant increase in lever presses for sodium in the progressive ratio 205 
experiment.  Using a cryostat, 1-mm punches of the brain regions of interest (VTA, 206 
accumbens shell and core, shown in Figure 1B) were collected from 300-µm sections.  207 
Punches were immersed in lysis buffer containing 25 mM Tris-HCl (pH 8), protease 208 
inhibitors (pepstatin, leupeptin, aprotinin), and phosphatase inhibitors (sodium 209 
pyrophosphate, sodium fluoride, sodium molybdate, phenylarsin oxide, and sodium 210 
orthovanadate).  The VTA and accumbens (shell and core) punches were immersed in 211 
50 and 100 uL of lysis buffer, respectively.  Brain punches were sonicated for three 212 
seconds followed by centrifugation at 14,000 rpm in 4C for 15 minutes.  Supernatant was 213 
collected and a Bicinchoninic acid (BCA) protein assay was performed on five microliters 214 
of each sample.  Based on the protein levels detected by the BCA assay, appropriate 215 
amounts of sample and sample buffer were loaded into wells of a 10% sodium dodecyl 216 
sulfate polyacrylamide gel.  Western blots for phospho- and total TH were performed 217 
using the LiCor Odyssey System. The following antibodies were used: monoclonal anti-218 
tyrosine hydroxylase antibody T2928 at 1:8000 (Sigma Aldrich); tyrosine hydroxylase 219 
pS31 rabbit polyclonal antibody #36-9900 at 1:400 (Life Technologies, Carlsbad, CA); 220 
IRDye 800CW Goat anti-Mouse IgG (H + L) 926-32210 at 1:2000 (Li-Cor Biosciences, 221 
Lincoln, NE); IRDye 680LT Goat anti-Rabbit IgG (H + L) 926-68021 at 1:4000 (Li-Cor 222 
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Biosciences). Phosphorylation sites on tyrosine hydroxylase generally increase 223 
catecholamine production.  Serine 31, the residue attended to in the present study, is 224 
phosphorylated by depolarization and extracellular receptor-activated kinases 1 and 2 225 
(Tekin et al., 2014). 226 
 227 
Statistical Analysis 228 
Data are presented as the mean ± the standard deviation of the mean.  For all 229 
experiments, comparisons were made between treatment variables with a two-way 230 
ANOVA.  When warranted, Bonferonni-corrected t-tests were performed.  Effect sizes 231 
were calculated using η2 and Cohen’s d.  All hypothesis tests used =0.05 as the criterion 232 
level of significance.  Statistical analyses were conducted using Prism 2.0 software (La 233 
Jolla, CA).   234 
 235 
Results 236 
 237 
The hormone regimen used in the present study was previously demonstrated to 238 
increase sodium ingestion in the Veh/AngII and DOC/AngII groups and to significantly 239 
water intake in the Veh/AngII condition (Grafe et al., 2014).  Here, the progressive ratio 240 
operant task was used to compare the effort rats are willing to exert for sodium ingestion 241 
after these hormone treatments.  Rats were pretreated with oil or DOC, followed by icv 242 
treatments of vehicle or AngII and allowed access to two levers: one for access to 3% 243 
saline and the other for access to water (0.1 ml per reinforcement).  Figure 2A illustrates 244 
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the cumulative number of lever presses across the duration of testing for 3% saline and 245 
water.  DOC/AngII treated rats bar-pressed for a longer duration for 3% saline compared 246 
with the other treatment groups.   247 
We conducted separate two-way ANOVA tests to examine effects of these 248 
hormones on bar presses for sodium and water.  The two-way ANOVA supported a main 249 
effect for AngII (F(1,29) = 13.9, p = 0.0008, η2 = 0.31) but not DOC (F(1,29) = 0.1, p = 250 
0.752, η2 > 0.01) on 3% saline lever presses.  Bonferroni-corrected post-hoc t tests 251 
revealed that the DOC/AngII group pressed significantly more on the saline lever 252 
compared with the Veh/Veh and DOC/Veh groups (Veh/Veh: 10.9 presses (SD2.4), 253 
DOC/Veh: 6.4 presses (SD1.7), Veh/AngII: 19.1 presses (SD6.4), DOC/AngII: 26.0 254 
presses (SD2.8); p = 0.001, p = 0.0001; d = 1.50).  A two-way ANOVA established a main 255 
effect for AngII (F(1,29) = 5.7, p = 0.023, η2 = 0.13) but not DOC (F(1,29) = 1.7, p = 0.203, 256 
η2 = 0.04) on water lever presses, and a significant interaction between the two hormones 257 
(F(1,29) = 8.4, p = 0.007, η2 = 0.19).  Post-hoc analysis revealed that rats treated with 258 
Veh/AngII pressed more for water than any other treatment group (Veh/Veh: 16.9 presses 259 
(SD5.2), DOC/Vehicle: 29.5 presses (SD4.9), Vehicle/AngII: 58.9 presses (SD10.7), 260 
DOC/AngII: 25.5 presses (SD8.9); p = 0.003, p = 0.020, p = 0.030; d = 1.47).   261 
With a progressive ratio schedule, the response requirement to attain rewards 262 
increases according to the same rule throughout the test session until the rat stops 263 
responding (Sclafani and Ackroff, 2003).  The highest set of bar presses completed is 264 
referred to as the break point and provides a measure of incentive.  In the present 265 
experiment, rats had simultaneous access to work for sodium and water.  Treatments for 266 
Veh/Veh, DOC/Veh and Veh/AngII elicited more work for water compared with sodium, 267 
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whereas the DOC/AngII-treated animals exhibited the opposite pattern.  A two-way 268 
ANOVA established an interaction between AngII and DOC (F(1,29) = 4.6, p = 0.046; 269 
F(1,29) = 8.6, p = 0.006; η2 = 0.18).  DOC/AngII treated rats had significantly higher ratio 270 
of the breakpoint for sodium versus breakpoint for water than all other treatment groups.   271 
 272 
Experiment 2: Hormone-Induced cFos expression  273 
The observed unique effect of DOC/AngII treatment on willingness to work for 274 
sodium versus water suggested an underlying difference in mesolimbic activity.  As 275 
shown in Figure 3, the number of cFos labeled cells was quantified in the VTA and the 276 
accumbens after Veh/Veh, DOC/Veh, Veh/AngII, and DOC/AngII treatment.  A two-way 277 
ANOVA supported a main effect for AngII (F(1,13) = 39.94, p < 0.0001, η2 = 0.64), but 278 
not for DOC or an interaction between the two hormones in the VTA.  Post hoc tests 279 
indicated that Veh/AngII and DOC/AngII treatments increased cFos expression compared 280 
with Veh/Veh (p = 0.0001, p = 0.0003, respectively; d = 3.77).   In the nucleus accumbens 281 
core, a two-way ANOVA revealed a main effect for AngII (F(1,13) = 12.82, p = 0.0034, η2 282 
= 0.44), but no effect for DOC or their interaction on cFos expression.  Post-hoc tests 283 
indicated that Veh/AngII and DOC/AngII treatments increased cFos levels compared to 284 
Veh/Veh (p = 0.0004, p = 0.0046, respectively; d = 2.12).  Lastly, a two-way ANOVA for 285 
the nucleus accumbens shell revealed a main effect for AngII (F(1,13) = 18.6, p = 0.0008, 286 
η2 = 0.52), but no effect for DOC or the two-hormone interaction on cFos expression.  287 
Post-hoc t tests indicated that each AngII treatment group induced significant cFos 288 
expression compared to the Veh/Veh treatment (Veh/AngII p = 0.0012; DOC/AngII p = 289 
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0.002; d = 2.48).  To summarize, AngII treatment activated cFos expression in the VTA 290 
and nucleus accumbens, but DOC pretreatment did not enhance this activation. 291 
 292 
Experiment 3: Hormone Regulation of Tyrosine Hydroxylase 293 
The AngII-induced expression of cFos of the VTA observed in Experiment 2 294 
suggested a possible increase in dopamine neurotransmission.  The level of tyrosine 295 
hydroxylase, the rate-limiting enzyme for dopamine production, and its phosphorylation, 296 
were measured by western blot analysis.  Rats were pretreated with vehicle or DOC 297 
followed by icv injections of vehicle or AngII, and tissue punches were collected five 298 
minutes after the last injection.  In the VTA, where dopaminergic neurons reside, a two-299 
way ANOVA supported a main effect for both DOC and AngII on tyrosine hydroxylase 300 
levels in the VTA (F(1,8) = 16.6, p = 0.004, η2 = 0.51; F(1,8) = 6.0, p = 0.04, η2 = 0.19), 301 
as illustrated in Figure 4A.  Post hoc tests indicated each treatment group significantly 302 
enhanced tyrosine hydroxylase levels compared with vehicle (p = 0.003, p = 0.04, p = 303 
0.02 for DOC/Veh, Veh/AngII, and DOC/AngII, respectively; d = 1.99).  However, DOC 304 
pretreatment did not further enhance the effects of AngII on tyrosine hydroxylase levels.  305 
For phospho-tyrosine hydroxylase, the value for each animal, as determined by western 306 
blot analysis, was divided by the value for total tyrosine hydroxylase (p-TH/TH).  In the 307 
VTA, a two-way ANOVA supported a main effect for DOC (F(1,8) = 10.37, p = 0.012, η2 308 
= 0.52), but not AngII treatment, as shown in Figure 4B.  Post-hoc analysis indicated that 309 
in the VTA DOC/AngII groups displayed increased p-TH/TH levels compared with 310 
Veh/Veh (p = 0.02; d = 0.78). 311 
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In the nucleus accumbens core, neither DOC nor AngII had a significant main 312 
effect on tyrosine hydroxylase levels.  In the shell of the nucleus accumbens, DOC, but 313 
not AngII, had a main effect on levels of tyrosine hydroxylase (F(1,8) = 9.3, p = 0.02, η2 314 
= 0.40).  Post-hoc analysis revealed DOC/Veh increased tyrosine hydroxylase levels 315 
compared with Veh/Veh (p = 0.04; d = 2.17).  In both the core and shell DOC and AngII 316 
treatments significantly increased p-TH/TH compared with vehicle (Core: Veh/Veh: 0.02 317 
(SD0.2), DOC/Veh: 0.42 (SD0.2), Veh/AngII: 0.37 (SD0.14), DOC/AngII: 0.38 (SD0.01), 318 
p = 0.011, p = 0.020, p = 0.018; d = 0.72); (Shell: Veh/Veh: 0.07 (SD0.05), DOC/Veh: 319 
0.46 (SD0.02), Veh/AngII: 0.38 (SD0.06), DOC/AngII: 0.39 (SD0.04); p = 0.0008, p = 320 
0.0028, p = 0.0022, respectively; d = 0.51).  In summary, in both regions of the nucleus 321 
accumbens, DOC and AngII pretreatments increased phosphorylation levels of tyrosine 322 
hydroxylase, usually without detectably increasing total tyrosine hydroxylase levels. 323 
 324 
Discussion 325 
 326 
During sodium deficiency, aldosterone and AngII act in concert to produce an avid 327 
consumption of sodium (Fluharty and Sakai, 1995), and combined treatment with these 328 
hormones is a useful experimental model for investigating the biological basis of this 329 
striking example of motivated behavior.  The current experiments tested the overall 330 
hypothesis that DOC and AngII treatments uniquely affect the willingness to work for 331 
access to sodium, potentially by modulating neural activation and neurochemistry in the 332 
mesolimbic dopamine pathway.  DOC/AngII-treated rats steadily exerted effort for access 333 
to 3% sodium solution while decreasing their effort for access to water compared with the 334 
 17 
Veh/AngII-treated rats. DOC and AngII had differential effects on cFos activation and 335 
phospho-tyrosine hydroxylase levels in the VTA.  Additive effects of DOC and AngII were 336 
not observed when these treatments were combined, although it is possible that cFos 337 
immunohistochemistry and tyrosine hydroxylase immunoblots were limited by a ceiling 338 
effect.  Instead, the co-treatment of DOC and AngII was associated with a unique 339 
combination of enhanced dopamine synthetic capacity and neural activation.  Figure 5 340 
summarizes these results according to hormone treatment, brain region and behavior. 341 
Several caveats are well known for the interpretation of cFos expression.  First, 342 
neuronal activation may occur without cFos induction.  Thus, the lack of cFos activation 343 
after DOC treatment may not reflect the recent activity of these neurons.  In addition, the 344 
neural consequences of cFos activation are not fully understood, making cFos merely a 345 
marker of recent activity.  Thirdly, without knowing the phenotype of the cFos labeled 346 
neurons in this study, the increased activity may occur in excitatory or inhibitory neurons, 347 
which would have quite different physiological consequences. With those points 348 
notwithstanding, cFos expression in the VTA and ventral striatum has been a valuable a 349 
proxy for measuring neuronal activation in many studies (Kovács, 2008). 350 
 351 
Behavioral mechanisms 352 
 Healthy rats normally avoid concentrated sodium solutions (Berridge et al., 1984); 353 
however when levels of both mineralocorticoids and AngII are elevated, a robust sodium 354 
appetite emerges (Fluharty and Epstein, 1983; Shade et al., 2002).  A component of 355 
sodium appetite is altered gustatory hedonic processing, and subsequent increased 356 
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pleasure, of passively received oral sodium.  In the taste reactivity test, sodium appetite 357 
is associated with reduced gaping and increased pre-swallowing behaviors in response 358 
to orally presented sodium solutions (Berridge et al., 1984; Clark and Bernstein, 2006).  359 
Further evidence that sodium depletion increases the “liking” of concentrated sodium 360 
solutions is the depletion-specific response of neurons in the ventral pallidum, a brain 361 
region thought to encode pleasure, in response to sodium ingestion (Tindell et al., 2006).  362 
The ventral forebrain may contribute to the hormonal modulation of sodium as a tastant 363 
(Garcia et al., 2008; Geerling and Loewy, 2006; Lundy, 2008).    364 
In addition to enhanced palatability, sodium appetite includes a willingness to work 365 
for sodium.  For example, rats run faster along a runway to gain access to sodium after 366 
co-administration of aldosterone and AngII (Zhang et al., 1984).  In the progressive ratio 367 
test, the highest set of bar presses completed, referred to as the break point, provides a 368 
quantification of goal value (Hodos, 1961).  Progressive ratio schedules model foraging 369 
in a natural setting; as resources are consumed in a given area, more effort is required to 370 
obtain them.  This method has been used to quantify the motivation for sodium after body 371 
fluid depletion (Clark and Bernstein, 2006; Starr and Rowland, 2006).  The present 372 
experiment used a two-bottle progressive ratio task to document the effects of 373 
mineralocorticoids and AngII on the relative effort-value of 3% sodium solution versus 374 
water.  This preparation revealed a shift in effort-value, with AngII alone biasing the 375 
animals to exert more effort for water than sodium, whereas DOC/AngII treatment drove 376 
them to work more for 3% saline than water.  Unlike previous studies of sodium appetite 377 
that focused on the quantity of sodium ingested, the two-bottle progressive ratio task 378 
quantifies the competing drives for sodium and water without changing fluid balance.  379 
 19 
Differences in effort-value led us to investigate effects of mineralocorticoids and AngII on 380 
mesolimbic regions, a brain system that regulates effort-related behaviors (Barbano and 381 
Cador, 2006; Floresco et al., 2008; Kelley et al., 2005; Phillips et al., 2007; Salamone et 382 
al., 2009).   383 
In the present study, no simple correlation exists between the level of cFos 384 
activation in a specific brain region and behavior.  Rather, similar cFos levels were 385 
observed in the VTA and nucleus accumbens when animals would have been working 386 
for water versus sodium.  One interpretation of this finding is that cFos activation in the 387 
mesolimbic dopamine pathway represents a non-specific increase in willingness work.  388 
However, it remains uncertain whether the similar numbers of cFos labeled cells were of 389 
the same cell type.  Furthermore, despite the similarities in cFos levels despite during 390 
these different motivated states, it should be noted that regulation of tyrosine hydroxylase 391 
varies, suggesting differential dopamine transmission.  Thus, further studies are needed 392 
to understand the details of motivation-specific regulation of mesolimbic dopamine. 393 
  394 
Hormone-sensing brain regions 395 
The initial brain targets of mineralocorticoids and AngII are known.  Regarding 396 
mineralocorticoids, the nucleus of the solitary tract contains a unique population of 397 
neurons that co-express mineralocorticoid receptors and the enzyme necessary for 398 
mineralocorticoid-specific action, known as 11- hydroxysteroid dehydrogenase 2 399 
(Geerling et al., 2006; Geerling and Loewy, 2006).  In contrast, humoral AngII acts initially 400 
on AngII type 1 (AT1) receptors in circumventricular organs, such as the subfornical organ 401 
 20 
and the organ vasculosum of the lateral terminalis (Lind et al., 1985; McKinley et al., 402 
1992b; Tanaka et al., 1986; Weiss and Hatton, 1990).  Mineralocorticoids exert minor up-403 
regulation of AT1 receptor levels and AT1 signaling (Grafe et al., 2014; Shelat et al., 404 
1999a; Shelat et al., 1998; Shelat et al., 1999b).  As a parallel mechanism, 405 
mineralocorticoids may exert a cooperative behavioral effect with AngII by acting 406 
elsewhere in a broader circuit.  For example, mineralocorticoids appear to remove an 407 
inhibitory influence on sodium appetite, namely oxytocin activity in the PVN (Blackburn et 408 
al., 1992; Grafe et al., 2014; Roesch et al., 2001; Stricker and Verbalis, 1987).   409 
A behaviorally relevant downstream connection of both mineralocorticoid- and 410 
AngII-sensing brain regions is the lateral hypothalamus (Camacho and Phillips, 1981), 411 
which is essential for the normal expression of sodium appetite (Dayawansa et al., 2011).  412 
The lateral hypothalamus, in turn, projects to the mesolimbic dopamine system via the 413 
medial forebrain bundle (Berk and Finkelstein, 1981; Saper et al., 1979).  Relevant 414 
projections from the lateral hypothalamus to the VTA may include orexin neurons (Fadel 415 
and Deutch, 2002; Narita et al., 2006; Peyron et al., 1998), which promote incentive-416 
based effort in the VTA (Borgland et al., 2009; Choi et al., 2010).  Furthermore, stimulation 417 
of the lateral hypothalamus promotes sodium appetite (Liedtke et al., 2011).  Likewise, 418 
AngII treatment enhances the release of striatal dopamine in freely moving rats within 419 
minutes, which then is associated with increased drinking behavior (Brown et al., 1996; 420 
Hoebel et al., 1994).  Thus, a possible link between mineralocorticoid and AngII-sensing 421 
brain regions and midbrain dopamine neurons may be lateral hypothalamic orexin 422 
neurons.  Future studies are needed to illuminate the details of this broader circuit.  423 
 424 
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Sodium appetite and motivation systems 425 
The mesolimbic pathway is part of a motor loop that links the incentive properties 426 
of stimuli with the effort exerted to approach or avoid them (Berridge, 2007; Salamone et 427 
al., 2007).  Neural adaptations in this brain region are associated with motivated 428 
behaviors (Gu et al., 2010).  AngII-induced cFos expression in the mesolimbic area is 429 
likely the result of transynaptic activation because the VTA does not have AngII receptors 430 
(Song et al., 1992).  Previous studies documented AngII-induced activation of the 431 
hypothalamus and taste nuclei (Han and Rowland, 1995; Houpt et al., 1998; McKinley et 432 
al., 1992a; Thunhorst et al., 1998; Vivas et al., 1995), but this is the first report of cFos 433 
activation in the VTA.   434 
The VTA includes many dopaminergic neurons (Oades and Halliday, 1987).  The 435 
AngII-induced increase in tyrosine hydroxylase levels supports the notion that dopamine 436 
neurons are activated by AngII treatment.  A similarly rapid increase in tyrosine 437 
hydroxylase levels occurs during exposure to cocaine-paired contexts (Liang et al., 2012).  438 
AngII-induced cFos expression may contribute to the up-regulation of tyrosine 439 
hydroxylase (Gheea et al., 1998).  DOC treatment markedly increased the 440 
phosphorylation of tyrosine hydroxylase, which augments catalytic activity of this rate-441 
limiting enzyme (Dunkley et al., 2004).   The combined actions of AngII and DOC on 442 
neuronal activation and tyrosine hydroxylase would be expected to produce a substantial 443 
increase in dopamine release at axonal targets.  Future studies are needed to examine 444 
the consequences of these hormonal actions at downstream nodes in the motivation 445 
circuit. 446 
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Regarding the ventral striatum, neurons there exhibit neural plasticity during 447 
various motivational states, including depletion-induced sodium appetite (Roitman et al., 448 
2002).  As in the VTA, AngII treatment increased cFos levels without a detectable 449 
augmentation by DOC pretreatment.  Unlike the VTA, all hormone treatments increased 450 
phosphorylation of tyrosine hydroxylase levels with detectable increases in total levels of 451 
this enzyme. It will be important for future studies to investigate the neurophysiological 452 
consequences and potential rewiring that may occur in the accumbens in response to 453 
AngII- versus DOC/AngII-induced changes in this dopamine pathway. 454 
 455 
Conclusions 456 
In summary, the DOC/AngII-induced sodium appetite involves a shift in the effort 457 
value of sodium versus water consumption, noted in the break point for lever pressing.  458 
DOC and AngII affect the mesolimbic dopamine pathway differently, with AngII treatment 459 
increasing cFos activation in the VTA and nucleus accumbens, and DOC increasing 460 
phosphorylation of tyrosine hydroxylase.  Thus, these two hormones may act in parallel 461 
to enhance mesolimbic dopamine transmission through complementary mechanisms. 462 
 463 
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Figure Legends 697 
 698 
Figure 1. Drawings of rat brain coronal sections depicting the regions of interest for both 699 
cFos immunohistochemistry (Panel A) and tyrosine hydroxylase activation assays (Panel 700 
B).  Panel A.  Boxes surrounding each brain region represent the areas analyzed for 701 
cFos cell counts.  Panel B.  Circles within each brain region represent 0.75-mm 702 
micropunches collected for the tyrosine hydroxylase western blots.  The brain regions 703 
examined include both the core and shell of the accumbens, as well as the VTA.  704 
Abbreviations: AcbC = Core of the accumbens, AcbS = Shell of the accumbens, CPu= 705 
caudate putamen, ml = medial lemniscus, LS = lateral septal nucleus, PAG = 706 
periaqueductal gray, VTA= ventral tegmental area.   707 
 708 
Figure 2.  DOC/AngII treatment increases relative motivation for sodium (n = 5-6/group). 709 
Panel A. Line graphs illustrating cumulative presses over time for 3% Saline and Water 710 
after Vehicle, DOC, AngII, or DOC plus AngII treatments.  Panel B. Bar graphs illustrating 711 
total lever presses for 3% saline and water after Vehicle, DOC, AngII, or DOC plus AngII 712 
treatments.  AngII-only treatment increased bar presses for water and sodium, whereas 713 
DOC plus AngII treatment mainly increased presses for sodium. Panel C. Bar graphs 714 
illustrating the breakpoint ratio of sodium to water after Vehicle, DOC, AngII, or DOC plus 715 
AngII.  DOC plus AngII causes the highest sodium to water breakpoint ratio.    716 
Abbreviations: AngII= Angiotensin II, DOC = deoxycorticosterone acetate, Veh = vehicle. 717 
 718 
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Figure 3.  DOC/AngII treatment increases cFos expression in the ventral tegmental area 719 
and the accumbens (n = 3-6 per group). Bar graphs illustrate the cFos cell counts in the 720 
ventral tegmental area and accumbens after either vehicle or DOC pretreatment followed 721 
by icv vehicle or AngII.  Representative images of the VTA and accumbens (coronal 722 
plane, 10x) in each treatment condition are shown above the bar graphs.  AngII and 723 
DOC/AngII treatment increased cFos expression in the VTA, with DOC/AngII inducing the 724 
most immunostaining. In the core and shell of the nucleus accumbens, each hormone 725 
treatment induced cFos immunostaining compared with vehicle; DOC/AngII induced the 726 
highest amount of cFos immunostaining.  Asterisks indicate a significant increase 727 
compared with the Veh/Veh group.  Abbreviations: AngII = Angiotensin II, DOC = 728 
deoxycorticosterone acetate, NuAcc= Accumbens, Veh = Vehicle, VTA= Ventral 729 
Tegmental Area 730 
 731 
Figure 4. DOC treatment increases tyrosine hydroxylase activation in the VTA and the 732 
accumbens (n = 3/group).  Panel A. Bar graphs illustrate tyrosine hydroxylase levels in 733 
the VTA and the accumbens (core and shell) after oil versus DOC pretreatment and icv 734 
saline versus AngII.  Representative western blot images of tyrosine hydroxylase are 735 
shown above each quantified bar.  Each treatment increased tyrosine hydroxylase 736 
expression in the VTA. Panel B. Bar graphs illustrate phosphorylated tyrosine 737 
hydroxylase levels in the VTA and the accumbens (core and shell) after either oil or DOC 738 
pretreatment followed by icv treatments with AngII.  Only DOC pretreatment significantly 739 
increased phosphorylated tyrosine hydroxylase expression compared to vehicle in the 740 
VTA and accumbens core.  However, each treatment increased phosphorylated tyrosine 741 
 35 
hydroxylase expression in the accumbens shell.  Panel C. Representative western blot 742 
images labeled with corresponding treatment groups and brain regions assayed for 743 
tyrosine hydroxylase (left) and phosphorylated tyrosine hydroxylase (right). 744 
Abbreviations: AngII = Angiotensin II, Acc= Accumbens, DOC = deoxycorticosterone 745 
acetate phospho-TH = phosphorylated tyrosine hydroxylase, TH = tyrosine hydroxylase, 746 
Veh = Vehicle, VTA= ventral tegmental area.  Asterisks indicate p<0.05 compared with 747 
the Veh/Veh group. 748 
 749 
Figure 5. Diagram summarizing the effects of DOC and AngII on the mesolimbic system 750 
and behavior.  Abbreviations: AngII = Angiotensin II, NuAcc= Nucleus Accumbens, DOC 751 
= deoxycorticosterone acetate, p-TH = phosphorylated tyrosine hydroxylase, TH = 752 
tyrosine hydroxylase, VTA= ventral tegmental area. 753 
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